An up-to-date overview of computational polypharmacology in modern drug discovery. (1st September 2020)

• Record Type: Journal Article
• Authors: Chaudhari, Rajan; Fong, Long Wolf; Tan, Zhi; Huang, Beibei; Zhang, Shuxing
• Is Part Of: Expert opinion on drug discovery. Volume 15:Number 9(2020)
• Page Start: 1025
• Page End: 1044
• Publication Date: 2020-09-01
• Subjects: Drug Polypharmacology -- multi-targeting Design -- drug Repurposing -- artificial Intelligence -- deep Learning -- multi-omics -- network Pharmacology -- molecular Promiscuity -- off-targets; 615.1
• DOI: 10.1080/17460441.2020.1767063
• Languages: English
• ISSNs: 1746-0441

Abstract

ABSTRACT: Introduction: In recent years, computational polypharmacology has gained significant attention to study the promiscuous nature of drugs. Despite tremendous challenges, community-wide efforts have led to a variety of novel approaches for predicting drug polypharmacology. In particular, some rapid advances using machine learning and artificial intelligence have been reported with great success. Areas covered: In this article, the authors provide a comprehensive update on the current state-of-the-art polypharmacology approaches and their applications, focusing on those reports published after our 2017 review article. The authors particularly discuss some novel, groundbreaking concepts, and methods that have been developed recently and applied to drug polypharmacology studies. Expert opinion: Polypharmacology is evolving and novel concepts are being introduced to counter the current challenges in the field. However, major hurdles remain including incompleteness of high-quality experimental data, lack of in vitro and in vivo assays to characterize multi-targeting agents, shortage of robust computational methods, and challenges to identify the best target combinations and design effective multi-targeting agents. Fortunately, numerous national/international efforts including multi-omics and artificial intelligence initiatives as well as most recent collaborations on addressing the COVID-19 pandemic have shown significant promise to propel the field of polypharmacology forward.